Literature DB >> 35878728

Engineered extracellular vesicles and their mimetics for cancer immunotherapy.

Chunping Liu1, Yichao Wang2, Longmei Li3, Dongyue He3, Jiaxin Chi3, Qin Li3, Yixiao Wu4, Yunxuan Zhao3, Shihui Zhang3, Lei Wang5, Zhijin Fan6, Yuhui Liao7.   

Abstract

Extracellular vesicles (EVs) are heterogeneous membranous vesicles secreted by living cells that are involved in many physiological and pathological processes as intermediaries for intercellular communication and molecular transfer. Recent studies have shown that EVs can regulate the occurrence and development of tumors by transferring proteins, lipids and nucleic acids to immune cells as signaling molecules. As a new diagnostic biomarker and drug delivery system, EVs have broad application prospects in immunotherapy. In addition, the breakthrough of nanotechnology has promoted the development and exploration of engineered EVs for immune-targeted therapy. Herein, we review the uniqueness of EVs in immune regulation and the engineering strategies used for immunotherapy and highlight the logic of their design through typical examples. The present situation and challenges of clinical transformation are discussed, and the development prospects of EVs in immunotherapy are proposed. The goal of this review is to provide new insights into the design of immune-regulatory EVs and expand their application in cancer immunotherapy.
Copyright © 2022 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cancer immunotherapy; Exosomes; Extracellular vesicles; Immune reprogramming; Immunogenic cell death

Mesh:

Substances:

Year:  2022        PMID: 35878728     DOI: 10.1016/j.jconrel.2022.05.062

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   11.467


  3 in total

Review 1.  Immunogenic cell death (ICD)-inducers in non-small-cell lung carcinoma (NSCLC): current knowledge and future perspective.

Authors:  Alireza Kashefizadeh; Hossein Kazemizadeh
Journal:  Clin Transl Oncol       Date:  2022-09-30       Impact factor: 3.340

2.  A molecular modeling on the potential application of beryllium oxide nanotube for delivery of hydroxyurea anticancer drug.

Authors:  Mustafa M Kadhim; Ali Jihad; Safa K Hachim; Sallal A H Abdullaha; Taleeb Zedan Taban; Ahmed Mahdi Rheima
Journal:  J Mol Model       Date:  2022-10-12       Impact factor: 2.172

3.  Phytochemical and toxicological evaluation of Zephyranthes citrina.

Authors:  Muhammad Haseeb Ur Rehman; Uzma Saleem; Bashir Ahmad; Memoona Rashid
Journal:  Front Pharmacol       Date:  2022-09-23       Impact factor: 5.988

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.